Skip to main content

Calreticulin Antibody (6C6)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-50053

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 6C6

Concentration

1 mg/ml

Product Specifications

Immunogen

Calreticulin Antibody (6C6) was developed against a synthetic peptide VESGSLEDDWDFLPPKKI corresponding to amino acids 191-208 of human Calreticulin, including the LC3 interacting region or LIR. [UniProt# P27797]

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

48 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for Calreticulin Antibody (6C6)

Western Blot: Calreticulin Antibody (6C6) [NBP2-50053]

Western Blot: Calreticulin Antibody (6C6) [NBP2-50053]

Western Blot: Calreticulin Antibody (6C6) [NBP2-50053] - Analysis of NBP2-50053 in HEK293 (lane 1), 3T3 (lane 2), SHSY-5Y (lane 3) and HeLa cells (lane 4). NBP2-50053 binds strongly to Calreticulin in 50 kDa.
Immunocytochemistry/ Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053]

Immunocytochemistry/ Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053]

Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053] - Analysis of of SH-SY5Y cells stained with mouse mAb to calreticulin, NBP2-50053, dilution 1:500 in green and costained with chicken pAb to lamin A/C, dilution 1:2,000 in red. The blue is DAPI staining of nuclear DNA. The MCA-6C6 antibody reveals granular staining of cytoplasm, while the lamin AC antibody stains the nuclear lamina and membrane.
Immunocytochemistry/ Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053]

Immunocytochemistry/ Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053]

Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (6C6) [NBP2-50053] - HeLa cell cultures were stained with NBP2-50053 (red). Calreticulin predominately localized in vesicles and the ER. Cells were counterstained with chicken polyclonal antibody to Vimentin (NB300-223, green). Blue is a DNA stain.

Applications for Calreticulin Antibody (6C6)

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:1000 - 1:5000

Immunohistochemistry

1:1000-1:5000

Western Blot

1:1000 - 1:5000

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50% PBS, 50% glycerol

Preservative

0.035% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Calreticulin

Calreticulin, also called CALR, is an endoplasmic reticulum (ER) protein that functions as a calcium (Ca2+) buffering molecular chaperone (1-3). Together with calnexin and ERp57, calreticulin has a critical role in protein folding and quality control of newly synthesized glycoproteins (1-3). Calreticulin has many diverse functions beyond Ca2+ binding, including cell adhesion, lectin binding, apoptosis, nuclear transport, antigen presentation, and immune response (1-3). Specifically, calreticulin is part of the peptide-loading complex that resides on the ER membrane and is responsible for antigen loading onto MHC class I molecules (1-3). Calreticulin protein has a theoretical molecular weight of 46 kDa and is 417 amino acids (aa) in length (1-3). The protein has three main domains: the N-terminal lectin-like domain, the proline-rich P-domain, and the acidic C-domain which is followed by an ER-retention KDEL signal sequence (1-3).

Given its role in multiple biological processes, it makes sense that calreticulin is implicated in both healthy and disease states. Studies have found that calreticulin mutations were present in patients with myeloproliferative neoplasms (MFN) and essential thrombocythaemia (ET) (4). Calreticulin expression is typically upregulated in most cancer lines, however it is downregulated in some tissues including cervical carcinomas, prostate cancer, and human colon adenocarcinoma (3). High expression of calreticulin on cancer cells is related to tumor cell phagocytosis and is often correlated with, and counteracted by, elevated CD47 expression to prevent cancer cell phagocytosis (3). Calreticulin mutations can serve as a major diagnostic biomarker for MFN and ET and additionally the calreticulin gene may be a potential target for cancer therapeutics (3,4).

References

1. Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I., & Opas, M. (2009). Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. The Biochemical Journal. https://doi.org/10.1042/BJ20081847

2. Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021). Calreticulin and cancer. Cell Research. https://doi.org/10.1038/s41422-020-0383-9

3. Sun, J., Mu, H., Dai, K., & Yi, L. (2017). Calreticulin: a potential anti-cancer therapeutic target. Die Pharmazie. https://doi.org/10.1691/ph.2017.7031

4. Prins, D., Gonzalez Arias, C., Klampfl, T., Grinfeld, J., & Green, A. R. (2020). Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere. https://doi.org/10.1097/HS9.0000000000000333

Alternate Names

Autoantigen Ro, CALR, Calregulin, cC1qR, CRT, SSA, Vasostatin

Gene Symbol

CALR

UniProt

Additional Calreticulin Products

Product Documents for Calreticulin Antibody (6C6)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Calreticulin Antibody (6C6)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...